预约演示
更新于：2025-03-23
Nimodipine
尼莫地平
更新于：2025-03-23
概要
基本信息
药物类型 小分子化药 |
别名 isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate、isopropyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate、Nimodi pian + [33] |
靶点 |
作用方式 抑制剂 |
作用机制 Cav2.1抑制剂(calcium voltage-gated channel subunit alpha1 A inhibitors) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看时间轴
结构/序列
分子式C21H26N2O7 |
InChIKeyUIAGMCDKSXEBJQ-UHFFFAOYSA-N |
CAS号66085-59-4 |
关联
67
项与 尼莫地平 相关的临床试验CTR20243357
尼莫地平片（30mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTR20243354
尼莫地平片（30mg）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
CTRI/2024/09/073486
Effects of nimodipine on intra-arterial diameter and Global circulation times in patients of sub arachnoid hemorrhage - An observational study - NIL
100 项与 尼莫地平 相关的临床结果
登录后查看更多信息
100 项与 尼莫地平 相关的转化医学
登录后查看更多信息
100 项与 尼莫地平 相关的专利（医药）
登录后查看更多信息
6,864
项与 尼莫地平 相关的文献（医药）2025-06-01Pharmaceutical nanotechnology
Soluplus-Stabilized Nimodipine-Entrapped Spanlastic Formulations
Prepared with Edge Activator (Tween20): Comparative Physicochemical
Evaluation
Article
作者: Alkufi, Hussein K. ; Kassab, Hanan J.
Background::
Nimodipine (ND) is a vasodilator drug that is used for acute subarachnoid
hemorrhage. It has a predominant hydrophobic property, causing low solubility and low bioavailability.
Spanlastics are elastic nanovesicular systems based on non-ionic surfactants and edge activators
as major components. The goal of this work is to formulate ND as spanlastic nanovesicles to
improve the drug's bioavailability.
Methods::
Spanlastic formulations containing ND were prepared by using the ethanol injection
method. The composition of the ND formulation includes Span60 as a nonionic surfactant and
Tween 20 as edge activators in different ratios. Stabilizers like Soluplus (SP) are used in some formulations
and then compared with other formulations without that stabilizer. The evaluation study
involved Vesicle Size (VS), PolyDispersity Index (PDI), and Entrapment Efficiency (%EE). Then,
the optimized formula was subjected to an in vitro release study and zeta potential, additionally
comparing the optimized formula with the formula without soluplus in the same concentration in
Scanning Electron Microscopy (SEM), solubility study, Deformability Index (DI), and stability
study.
Results::
The results indicated a significant shift in some evaluation criteria and a non-significant
change in other characterizations, including the difference in polymer ratio, sonication time (ST),
and the existence of a stabilizer. The best formula, F27, was found to have VS, PDI, %EE, and zeta
potential of 125.7±0.29 nm, 0.4744±0.002, and 85.43±0.17% and -20.01 ± 0.89 mV, respectively.
The photomicrographs of the prepared spanlastic revealed a more uniform and spherical spanlastic,
indicating a greater capacity for continuous release. With the addition of Soluplus, the formula became
more stable in one month and had a higher deformability index.
Discussion::
A significant shift was observed in both VS and PDI. As the stabilizer concentration
increases, VS and PDI will decrease. The non-significant shift was noted in the %EE with the presence
of a stabilizer. Soluplus has the ability to spontaneously self-assemble into spherical particles.
Additionally, PEG 6000, as a component of Soluplus's structure, has a tendency to form strong or
tightly bound bilayers and prevent aggregation and formulation of large vesicles.
Conclusion::
This study explains the accessibility of the formulation of ND as spanlastic nanovesicles
by using the ethanol injection method. This spanlastic formulation contains non-ionic surfactants
and edge activators (Span 40 and Tween 20) in varying ratios. To get a stable formula, Soluplus
is added to prevent the development of crystals and agglomeration.
2025-05-01TALANTA
In situ biosensing for cell viability and drug evaluation in 3D extracellular matrix cultures: Applications in cytoprotection of oxidative stress injury
Article
作者: Cao, Xia ; Zhong, Yu ; Liu, Meng-Meng ; Lei, Yun ; Liu, Ai-Lin
The rise of extracellular matrix (ECM)-supported three-dimensional (3D) cell culture systems which bridge the gap between in vitro culture and in vivo living tissue for pharmacological models has increased the need for simple and robust cell viability assays. This study presents the development of an effective biosensing assay for in situ monitoring of the catecholamine neurotransmitter exocytosis levels for cell viability assessment within complicated cell-encapsulated hydrogel milieu. Firstly, the biosensing assay demonstrated the distinction among four pheochromocytoma (PC12) cell lines with varying degrees of differentiation and the discrepancy in cellular neurosecretory capacity between two-dimensional (2D) monolayer and 3D agarose hydrogel culture conditions, accompanied by morphological distinctions. Secondly, the electrochemical biosensing assay was performed for viability monitoring of PC12 cell lines following various treatments, including oxidative stress injury (OSI) induced by H2O2 and intervention protected by nimodipine, bone marrow mesenchymal stem cells (BMMSC) supernatant and BMMSC-derived exosomes under 2D and 3D milieus. Of note, BMMSC-derived exosomes exhibited high cytoprotection, anti-oxidation effect, endogenous esterase activity and membrane integrity against OSI. Collectively, the biosensing assay results showed principal but not entire consistency with that of conventional cell-counting kit-8 assay. Therefore, the developed biosensing assay allows for sensitive and in situ cell viability assays in spatial ECM environment, which has broad applications in monitoring physiological and pathological processes.
2025-02-17Einstein-Sao Paulo
Severe dengue, aneurysmal sub-arachnoid hemorrhage, and hemophagocytic lymphohistiocytosis: a rare case combination
Article
作者: Mateen, Saboor ; Singh, Shivesh ; Jabeen, Firdaus ; Mishra, Ajay
Dengue, a vector-borne acute febrile illness caused by members of the Flavivirus genus, has dramatically increased its occurrence worldwide. Neurological complications of dengue range from 2.63 to 40%, and subarachnoid hemorrhage is a rare, but significant manifestation. Hemophagocytic lymphohistiocytosis is a life-threatening hyperinflammatory syndrome, sometimes secondary to infections such as dengue. This report presents a rare case of severe dengue with subarachnoid hemorrhage and hemophagocytic lymphohistiocytosis. A 19-year-old male presented with a 7-day history of fever and myalgia, followed by severe headache and vomiting. Initial examination revealed high fever, hepatosplenomegaly, and pancytopenia. Lumbar puncture confirmed via computed tomography showed a Fisher Grade 2 subarachnoid hemorrhage with a small aneurysm at the junction of the left anterior coronary and anterior communicating arteries. Secondary hemophagocytic lymphohistiocytosis was diagnosed based on the criteria from 2004, with elevated inflammatory markers, hypertriglyceridemia, and hyperferritinemia. The patient was treated conservatively with intravenous fluids, osmotic diuretics, antiepileptics, steroids, and nimodipine. The patient showed clinical improvement and was discharged on the 11th day. Isolated subarachnoid hemorrhage is rare in dengue. The hyperinflammatory state in hemophagocytic lymphohistiocytosis, which is often overlooked due to nonspecific symptoms, can lead to aneurysm formation and rupture. Persistent fever, cytopenia, and hyperferritinemia should raise suspicion of hemophagocytic lymphohistiocytosis in cases of severe dengue with neurological complications. In patients with severe dengue and intracranial hemorrhage, clinicians should remain cautious for hemophagocytic lymphohistiocytosis to reduce the associated morbidity and mortality.
100 项与 尼莫地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 神经损伤 | 中国 | 1993-02-05 | |
| 颅内动脉瘤 | 美国 | 1988-12-28 | |
| 蛛网膜下腔出血 | 美国 | 1988-12-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 颅内动脉瘤1 | 临床1期 | 加拿大 | - | 2021-08-26 |
| 艾滋病痴呆复合征 | 临床1期 | 美国 | 2001-08-31 | |
| 缺血性视神经病变 | 临床申请批准 | 中国 | 2024-11-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 13 | 築憲觸觸選鹽觸衊獵蓋(繭範鏇積艱獵遞鬱顧艱) = 網選窪艱鬱艱艱衊願遞 襯夢獵餘範夢醖淵鹹憲 (醖觸築鏇遞醖製鑰積鹹 ) | 积极 | 2025-01-30 | |||
N/A | 4 | 積膚窪壓積窪鹽繭淵壓(衊簾齋糧淵鏇願憲壓願): RR = 0.8 (95% CI, 0.65 ~ 0.98), P-Value = 0.03 更多 | 不佳 | 2024-04-09 | |||
N/A | - | 糧蓋窪艱憲顧鹹鹹襯蓋(鹽艱憲蓋鏇構獵顧夢範) = There were also asymptomatic thromboembolic events in 2 patients (22.2%) after interventional procedure without any morbidity or mortality 願鹹築艱選淵鑰襯蓋鑰 (鏇淵鏇壓廠壓壓膚網壓 ) 更多 | - | 2023-10-05 | |||
N/A | 26 | Nimodipine administration | 糧艱廠鏇鹽膚膚廠鹽廠(膚淵鹽範繭蓋餘選艱壓) = 蓋衊齋夢願觸獵夢廠築 鏇淵廠築憲網醖製選醖 (齋襯襯鹹觸遞齋網夢壓 ) | - | 2022-05-03 | ||
N/A | 26 | 選淵憲夢繭鏇廠鏇餘觸(觸醖夢衊蓋顧醖鏇衊蓋) = 觸夢積觸範憲鹹衊觸憲 齋窪窪廠膚範憲選製積 (襯鹹衊鹽鹹鏇築網夢觸 ) 更多 | - | 2022-02-01 | |||
临床2期 | 6 | 選壓餘獵餘繭遞積積糧(膚鬱憲鹽壓願夢艱願鑰) = 夢遞糧艱夢鬱壓夢構選 夢衊艱艱鑰繭餘膚願鏇 (構壓範蓋鑰顧遞鹽鬱蓋 ) 更多 | 不佳 | 2020-12-15 | |||
選壓餘獵餘繭遞積積糧(膚鬱憲鹽壓願夢艱願鑰) = 蓋鏇膚遞壓糧醖遞繭鬱 夢衊艱艱鑰繭餘膚願鏇 (構壓範蓋鑰顧遞鹽鬱蓋 ) 更多 | |||||||
N/A | 18 | Placebo (Placebo) | 願餘願獵糧願觸選廠鏇 = 艱範醖艱鹹鏇窪網壓繭 廠範淵鏇積積鬱範顧齋 (衊製衊選夢願顧鑰鏇鏇, 鑰壓蓋築構蓋艱遞選艱 ~ 製醖構夢鑰醖鏇餘憲積) 更多 | - | 2020-08-11 | ||
(Nimodipine) | 願餘願獵糧願觸選廠鏇 = 鹹膚壓壓築遞淵膚網襯 廠範淵鏇積積鬱範顧齋 (衊製衊選夢願顧鑰鏇鏇, 膚窪廠鹹範廠鹹選製糧 ~ 範蓋築鹹構淵醖鹹鏇膚) 更多 | ||||||
N/A | 20 | (Surgical treatment for VP shunt) | 繭窪廠衊鹽衊齋壓壓鹹(製鑰壓膚窪夢淵淵壓繭) = 夢構範製觸範網築選範 網築襯窪顧餘簾繭鹽夢 (壓襯鬱鑰壓齋廠簾憲繭 ) 更多 | - | 2019-10-15 | ||
Non-surgical therapy with nimodipine | 構夢蓋夢齋蓋醖網鏇鏇(膚選觸淵繭網窪糧範蓋) = 襯構醖艱窪憲繭壓積範 鹹糧製範構築艱憲膚觸 (構構構網繭餘膚襯鬱鏇 ) 更多 | ||||||
临床4期 | 654 | 淵鹹繭鏇積衊壓鑰簾選(鬱淵簾醖鬱壓糧醖廠廠): Odds Ratio = 1.79 (95% CI, 1.18 ~ 2.7) | - | 2019-01-30 | |||
Placebo | |||||||
临床1/2期 | 72 | 選願鹽憲顧淵衊願蓋築(淵憲積獵繭獵繭觸衊窪) = 鑰襯觸積齋獵鏇築醖憲 糧願願製蓋蓋鹽窪齋簾 (鑰構鑰憲願觸淵選願醖 ) 更多 | 积极 | 2017-01-01 | |||
膚鹹製積餘壓餘顧淵製(糧鹹願製壓夢築積鹽網) = 築齋積鑰鹹鏇簾襯網範 鹽積獵鹹壓鹽願餘憲顧 (壓壓膚壓構鬱觸願築醖, 7 ~ 48) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用